Abstract
In a randomized, parallel arm, open-label study, the effect of switching from ritonavir to either nelfinavir or nelfinavir plus saquinavir as part of a triple antiretroviral regimen was investigated in 16 patients with undetectable HIV-1 loads. Patients continued to use the same nucleoside reverse transcriptase inhibitors as before the switch of protease inhibitor. The period of follow-up was 48 weeks. In all patients HIV-1 load remained undetectable, whereas CD4 cell counts remained stable. Furthermore, lipid markers improved after the switch.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Anti-HIV Agents / therapeutic use
-
Drug Therapy, Combination
-
HIV Infections / drug therapy*
-
HIV Protease Inhibitors / therapeutic use*
-
HIV-1 / isolation & purification
-
HIV-1 / physiology
-
Humans
-
Nelfinavir / therapeutic use*
-
Reverse Transcriptase Inhibitors / therapeutic use
-
Ritonavir / therapeutic use*
-
Saquinavir / therapeutic use*
-
Treatment Outcome
-
Triglycerides / blood*
Substances
-
Anti-HIV Agents
-
HIV Protease Inhibitors
-
Reverse Transcriptase Inhibitors
-
Triglycerides
-
Nelfinavir
-
Saquinavir
-
Ritonavir